P. Kent Hawryluk - Sep 12, 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Role
President & CEO, Director
Signature
/s/ Richard Bartram, attorney-in-fact
Stock symbol
MBX
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
4
Date filed
9/13/2024, 05:06 PM
Next filing
Sep 17, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBX Stock Option (Right to Buy) Award $0 +120K $0.00 120K Sep 12, 2024 Common Stock 120K $16.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.